Infinity Pharmaceuticals Inc. Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Limited Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide

Published: Oct 26, 2010

CAMBRIDGE, Mass., Oct. 26, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940. Data from the Phase 1 single-dose study showed IPI-940 demonstrated favorable pharmacokinetics and was generally well tolerated in healthy volunteers. Purdue is planning to initiate Phase 2 studies of IPI-940 in 2011.

Back to news